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Your Article "Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared 
pathways with neuroaffective traits" has been seen by two referees. You will see from their comments 
below that, while they find your work of interest, they have raised some relevant points. We are 
interested in the possibility of publishing your study in Nature Genetics, but we would like to consider 
your response to these points in the form of a revised manuscript before we make a final decision on 
publication. 
 
To guide the scope of the revisions, the editors discuss the referee reports in detail within the team, 
including with the chief editor, with a view to identifying key priorities that should be addressed in 
revision and sometimes overruling referee requests that are deemed beyond the scope of the current 
study. In this case, we ask that you address all technical queries related to the association analyses 
and present further details on how the signals compare across different subgroups and cohorts with 
different diagnostic criteria. We also encourage you to examine sub-genome-wide significant variants 
from the discovery stage in the 23andMe cohort to potentially increase the yield of genome-wide 
significant loci in the combined analysis as suggested by Reviewer #1. We hope you will find this 
prioritized set of referee points to be useful when revising your study. Please do not hesitate to get in 
touch if you would like to discuss these issues further. 
 
We therefore invite you to revise your manuscript taking into account all reviewer and editor 
comments. Please highlight all changes in the manuscript text file. At this stage we will need you to 
upload a copy of the manuscript in MS Word .docx or similar editable format. 
 
We are committed to providing a fair and constructive peer-review process. Do not hesitate to contact 
2 
us if there are specific requests from the reviewers that you believe are technically impossible or 
unlikely to yield a meaningful outcome. 
When revising your manuscript: 
*1) Include a “Response to referees” document detailing, point-by-point, how you addressed each
referee comment. If no action was taken to address a point, you must provide a compelling argument.
This response will be sent back to the referees along with the revised manuscript.
*2) If you have not done so already please begin to revise your manuscript so that it conforms to our
Article format instructions, available
<a href="http://www.nature.com/ng/authors/article_types/index.html">here</a>.
Refer also to any guidelines provided in this letter.
*3) Include a revised version of any required Reporting Summary:
https://www.nature.com/documents/nr-reporting-summary.pdf
It will be available to referees (and, potentially, statisticians) to aid in their evaluation if the
manuscript goes back for peer review.
A revised checklist is essential for re-review of the paper.
Please be aware of our <a href="https://www.nature.com/nature-research/editorial-policies/image-
integrity">guidelines on digital image standards.</a> 
Please use the link below to submit your revised manuscript and related files: 
[REDACTED]
<strong>Note:</strong> This URL links to your confidential home page and associated information 
about manuscripts you may have submitted, or that you are reviewing for us. If you wish to forward 
this email to co-authors, please delete the link to your homepage. 
We hope to receive your revised manuscript within 6-8 weeks. If you cannot send it within this time, 
please let us know. 
Please do not hesitate to contact me if you have any questions or would like to discuss these revisions 
further. 
Nature Genetics is committed to improving transparency in authorship. As part of our efforts in this 
direction, we are now requesting that all authors identified as ‘corresponding author’ on published 
papers create and link their Open Researcher and Contributor Identifier (ORCID) with their account on 
the Manuscript Tracking System (MTS), prior to acceptance. ORCID helps the scientific community 
achieve unambiguous attribution of all scholarly contributions. You can create and link your ORCID 
from the home page of the MTS by clicking on ‘Modify my Springer Nature account’. For more 
information please visit please visit <a 
href="http://www.springernature.com/orcid">www.springernature.com/orcid</a>. 






















Referee #1: Genetics, common diseases, gastrointestinal disorders 
 






Remarks to the Author: 
 
Previous GWAS of IBS have yielded little in terms of robust genetic associations. This is an important 
study that identified some of the first genome-wide significant loci associated with IBS risk. The 
authors combined IBS GWAS results from UK Biobank with the Bellygenes consortium to identify six 
genome-wide significant loci, all of which replicated in an independent 23andMe cohort. Additional 
analyses suggested there was little sharing of genetic risk with other gastrointestinal diseases, but 




At ~200k cases, the 23andMe cohort is almost four times larger than the discovery cohorts. This 
seems like a missed opportunity to uncover a greater number loci and improve understanding of IBS 
biology. I can sympathize that there may be roadblocks in accessing full 23andMe summary statistics 
and performing meta-analysis, but was it not possible to look up sub genome-wide significant variants 
from the UKB+Bellygenes results in 23andMe, many of which would likely easily exceed p<5e-8 when 
combined? 
 
Related to the point above, it is a little unclear how many variants were looked up in 23andMe and 
how these variants were selected. Page 19 of the supplemental text states that “all but two of the 109 
variants submitted were matched in the 23andMe dataset.” Later on page 26 in the supplement, it 
implies that 22 independent associations were looked up (“N where N=22 associations”). In the main 
text, it implies that 12 variants (along with their proxies) were looked up - six loci from the primary 
analysis, and six loci that reached genome-wide significance in one of the subgroups. 
 








significant loci differ between various subgroups. Some of this information is captured in Figure S8, 
though I wonder whether using ORs and 95%CIs can better represent these data than Z-scores. For 
instance, it is not obvious whether a Z-score in one group is lower than another because of a larger SE 
or because the OR is closer to 1. Knowing whether the CIs overlap between certain groups would also 
be informative. To that end, I wonder if a Forest plot-like representation of this would be more 
suitable? 
 
Similarly, what was the degree of heterogeneity between the subgroups presented in Table S8 and the 
Bellygenes and 23andMe cohorts? The authors note that some associations detected in one subgroup 
do “Surprisingly... replicate in an independent dataset”. What were the effect sizes at these variants in 
Bellygenes and 23andMe? Is it possible to include these in the Forest plot as suggested above? 
 
I believe the lack of replication of the female-only association with unprompted self-report IBS from 
Bonfiglio et al. (2018) warrants further discussion. This seems more odd since the previous study used 
largely the same UKB dataset with a noisier definition of IBS. Did the authors also perform sex-
stratified analysis at this variant using their more comprehensive case definition? Were the results at 
this variant even nominally significant? Was it significant in their subgroup analysis using only 
unprompted self reports? 
 
Please clarify the number of controls in the discovery cohort. On line 173, it says there were 433,201 
controls in the discovery cohort (also repeated on line 344). However, summing the number of 
controls in UKB (360,845) and Bellygenes (139,981) gives a total of 500,826 controls (lines 175-176). 
 
Table S20 - please include an effect size column, or some other indication about direction of effect of 
the related phenotype relative to IBS (e.g. does the IBS risk-increasing allele of rs10156602 increase 
or decrease childhood BMI?). 
 
Given the strong genetic correlations with a range of neuro-related phenotypes, why did the authors 
only perform MR analysis on anxiety? Were MR results similar for IBS and the other phenotypes in 




In Table S13, some SE numbers are 0.00E+00 
 
Line 270-271. I understand what the authors are trying to convey, but I disagree with the statement 
that low SNP-heritability is reflected in the low ORs from this study. It is entirely possible in theory to 
have low SNP-heritability and large ORs if variants are rare. 
 
In the description of the GCTA COJO analysis in the supplemental text page 25, please provide the 
definition of “upstream”/“downstream”, and specify what individual-level genotype data were used as 














This paper reports the results of a large GWAS study of Irritable Bowel Syndrome (IBS) in the UK 
Biobank. The authors added a questionnaire to the UK Biobank to collect diagnostic information on the 
symptoms, subtypes and severity of IBS. GWAS of a broad phenotypic definition of IBS in the UK 
Biobank combined with another large hospital registry consortium, Bellygenes yielded 6 significant 
associations with SNPS that explained a small proportion of the variance of IBS (i.e., 5.6%). These 
findings were replicated in the large 23 and me sample using self-reported diagnosis of IBS. The other 
major focus of the paper was investigation of genetic overlap between IBS and anxiety, neuroticism 
and depression, which in the aggregate were found to share some genetic risk with IBS. 
 
This is an interesting paper that seeks to identify the genomics of gut diseases unexplained by well 
characterized genetic diseases such as Crohn’s and Ulcerative Colitis. As such, it is an idiopathic and 
likely heterogeneous group of conditions that have shared environmental and genetic factors with a 
range of other conditions as demonstrated in this report. The finding and replication of 6 loci advances 
the field and is of heuristic value for future studies of etiologic mechanisms underlying subsets of IBS. 
 
However, I found that the second component of the paper that linked IBS to “neuroaffective” 
conditions was less compelling. The phenotypes ranged from current symptom checklists for anxiety 
and depression that yield highly nonspecific rates of significant mood and anxiety disorders across 
varying time periods. Some of the questions are queried over the past 3 months, whereas others ask 
about the current two weeks. These scales can all be elevated due to multiple physical and 
psychological stressors and have very little relevance to true mental disorders including mood and 
anxiety disorders. To date, GWAS have not explained a substantial proportion of these conditions 
likely due to the heterogeneity of disorders that may lead to elevated symptoms of distress. Thus, 
taken together with the very low explanatory findings for IBS, the link with an even more 
heterogeneous group of conditions that may affect the brain does not really advance our 
understanding of etiologic factors underlying IBS. 
 
There are several specific issues that require clarification or discussion. 
 
1. It is unclear why the authors chose to combine across all of the subgroups of IBS for the GWAS 
analyses rather than examine the subtypes with greatest diagnostic certainty or severity. The 
exceedingly high prevalence rate of IBS of 14.5% was surprising and likely indicates a mixture of truly 
heritable cases and those that may be time limited symptom elevations. 
 
2. It was difficult to understand the samples and phenotypes for the IBS as well as psychological 
symptoms in the 3 samples, and how subsets were combined in the analyses. The Methods could 
include a more clear description so that the reader does not have to search the supplementary 
materials for this broad overview. 
 
3. The diagnoses of IBS were quite different in the three samples, ranging from medical records in the 
Bellygenes cohort to self-reported questionnaires with dome of the Rome criteria I the UK Biobank to a 
few questions in 23 and me. How confident are the authors that they are really tapping the same 
disorder using these diverse methods? 
 
4. The epidemiologic associations with IBS in the UK Biobank were quite interesting and could provide 
further insight into potential sources of heterogeneity. Could the subtypes of IBS be further 









5. The authors should discuss how the 50% response rate to the IBS questionnaire in the UK Biobank 
may have led to bias in the findings. 
 







Re: Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared pathways with
neuroaffective traits
Dear Kyle,
As per your invitation, we have attached a revised version of our manuscript, with changes and additions
highlighted in green. Below, we have included a point-by-point response to the reviewers’ comments.
We have introduced new data and clarified details in response to reviewers’ questions on the impact of
diagnostic criteria on our results. We are particularly happy with the forest plot suggested by reviewer 1, which
makes interpreting this data much easier. We have also included summary data across all case definitions for all
independent loci as a new table. In response to reviewer 2, we have analysed new case definitions (a
high-specificity analysis and a severe IBS analysis), which produce similar results to previous analyses. We have
re-written the Methods section to make our analyses easier to follow. We have clarified other technical details
requested by the reviewers. None of these alterations change the overall conclusions of our manuscript.
We were unfortunately unable to obtain additional replication data from 23andMe on sub-genome-wide
significant associations. Both the academic authors and our coauthors at 23andMe made significant efforts to
request this data in light of reviewer comments, via external and internal applications, but ultimately
discussions within the company concluded that providing this data would not be possible. This is obviously
disappointing, as we agree with the reviewer on the value this data would add. However, our analysis remains,
by far, the largest IBS genetic analysis ever performed, both in terms of sample size and yield of loci.
We have introduced other new analyses in response to reviewer comments. These include a more substantial
Mendelian Randomization analysis, demonstrating that the complex bidirectional causal effects seen between
anxiety and IBS generalizes to depression and neuroticism (though not to bipolar disorder and schizophrenia).
They also include a new analysis, in response to reviewer 2’s comments, demonstrating that genetic
correlations between IBS and anxiety and major depressive disorder are robust to case definition used, and are
not likely to be driven by effects unrelated to true mental disorders.
We are grateful to both reviewers for their detailed and constructive reviews, and for Nature Genetics for
inviting us to resubmit a revised manuscript. We feel that our paper has been substantially improved as a result
of the revisions that we have made, and (in our humble opinion) that this revised version would be a good
candidate for publication in your journal.
Yours sincerely,
Prof Miles Parkes Dr Luke Jostins Prof Mauro D’Amato





Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights
shared pathways with neuroaffective traits
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Reviewer #1:
Remarks to the Author:
Previous GWAS of IBS have yielded little in terms of robust genetic associations. This is an
important study that identified some of the first genome-wide significant loci associated with IBS
risk. The authors combined IBS GWAS results from UK Biobank with the Bellygenes consortium to
identify six genome-wide significant loci, all of which replicated in an independent 23andMe
cohort. Additional analyses suggested there was little sharing of genetic risk with other
gastrointestinal diseases, but significant sharing with neuro-related phenotypes such as anxiety
and depression.
We thank the reviewer for their positive comments on our manuscript.
Major comments:
At ~200k cases, the 23andMe cohort is almost four times larger than the discovery cohorts. This
seems like a missed opportunity to uncover a greater number loci and improve understanding of
IBS biology. I can sympathize that there may be roadblocks in accessing full 23andMe summary
statistics and performing meta-analysis, but was it not possible to look up sub genome-wide
significant variants from the UKB+Bellygenes results in 23andMe, many of which would likely
easily exceed p<5e-8 when combined?
We agree that study of sub-genome-wide significant variants from the discovery cohort in
the 23andMe panel would uncover a greater number of bona fide IBS loci. However,
23andMe have indicated that they are unable to provide details on sub-genome-wide
significant associations as part of this study due to their policy on replication and data
sharing. We had previously requested this at the point we were establishing our
collaboration with them three years ago. Following this specific reviewer comment our
23andMe collaborators made a further internal request for replication data on the 24
additional independent loci in our discovery cohort associated with IBS at p<1e-6.
Unfortunately, after discussions within 23andMe, this request was again declined. 23andMe
did, however, provide additional data regarding a new genome-wide significant locus
identified in the course of our analysis by ‘severe IBS’ as recommended by Reviewer 2 (see
below).
Related to the point above, it is a little unclear how many variants were looked up in 23andMe and
how these variants were selected. Page 19 of the supplemental text states that “all but two of the
109 variants submitted were matched in the 23andMe dataset.” Later on page 26 in the
supplement, it implies that 22 independent associations were looked up (“N where N=22
associations”). In the main text, it implies that 12 variants (along with their proxies) were looked
up - six loci from the primary analysis, and six loci that reached genome-wide significance in one of
the subgroups.
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We apologise for the confusion that these different numbers have caused, in retrospect this
was not well described. Below we have given a rather lengthy response (apologies again) to
explain where the numbers of 109 and 22 came from in the previous version of the
manuscript and fully explain our approach to this in the revised manuscript.
To consolidate genome-wide significant associations across our original analyses, we carried
out clumping these for each analysis individually. This yielded 36 sets of three variants (the
lead SNPs and two proxies), or 108 variants total (109 when the IBS-C analysis was included).
We then removed sets between which variants overlapped (retaining the set with the best
lead p-value), so as not to request data in duplicate. This produced 23 sets of variants (69
variants including proxies) that we sent to 23andMe for replication, of which 67 variants
were returned with data. These 67 SNPs contained or tagged all of the original 36 clumps
with r2>0.965. This is the data that is present in Table S13.
Two of these 23 sets of variants were in high LD (r2>0.9), so we decided to call this "22
independent loci" for the purposes of correcting for multiple testing in the previous version
of the manuscript. In practice, however, we do not know that these 22 sets of variants are
independent, as three other sets were in moderate LD (r2=0.2-0.9). On reflection, given that
our conditional analysis did not provide strong evidence that these loci in weak LD
represented multiple signals at the same locus, we have decided to merge these moderate
LD associations together into a list of 19 independent loci across all analyses. After adding in
the new locus from the severe IBS analysis suggested by Reviewer 2, this gives 20
independent loci.
As a result, the current version of our paper corrects for N=20 associations. All our
successfully replicated loci would replicate after correcting for 20, 22 or indeed 36
independent associations, so the results of the analysis are not sensitive to this choice.
We have now enumerated these 20 independent loci in Table S13 to make this easier to
follow. They include 14 from key analyses, which includes the discovery cohort (six, all
replicating) and other IBS definitions (eight, of which five replicate), all illustrated in the
forest plot requested by the reviewer (Figure S8, below). For clarity, we show the summary
statistics of these loci across these analyses in a new table (Table S14).
The 6 remaining loci came from GWAS of methodological variations (UKB cases in the
discovery cohort without correcting for DHQ response), IBS subtypes (severe IBS), or
intermediate traits used in the meta-analysis (Bellygenes tertiary care cohorts,
DHQ-respondents in the discovery cohort). Only this last definition yielded a replicating hit.
These data remain available in Table S13.
We have amended the Replication section in the supplement to more clearly explain which
variants were sent to 23andMe for replication:
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“Lead SNPs and two proxies for each independent association from each analysis
were sent to 23andMe for replication in a cohort with 205,252 self-reported IBS
cases and 1,384,055 controls. Across analyses,we sent 20 independent associations
for replication (min. 250kb apart, max. r2 of 0.2), which included 6 loci from the
discovery analysis, 8 loci from the additional key definitions shown in Fig. S8, 1 from
the severe IBS analysis, and 5 from GWAS of intermediate traits used in the
meta-analysis and methodological variations.
All but two of variants submitted for replication, marked with an asterisk in Table
S13, were matched in the 23andMe dataset. The variants missing from 23andMe
data (6:31610189_TAAAG_T, rs746685195) both had proxies with r2≥0.965 in our
dataset which were matched.
Associations were considered replicated if SNPs had identical directions of effect in
both datasets, were significant in the 23andMe data (p23andMe<0.05/N where N=20
associations), and remained genome-wide significant following meta-analysis
(pmeta<5e-8).”
We have also updated the results section to provide clarity:
“Eight additional loci showed genome-wide significant association with various IBS
definitions (see methods) but not the whole discovery cohort, of which five
replicated in 23andMe data (Fig. S8, Table S13, Table S14).”
Given the different IBS definitions, I am interested in how the effect sizes at the genome-wide
significant loci differ between various subgroups. Some of this information is captured in Figure S8,
though I wonder whether using ORs and 95%CIs can better represent these data than Z-scores. For
instance, it is not obvious whether a Z-score in one group is lower than another because of a larger
SE or because the OR is closer to 1. Knowing whether the CIs overlap between certain groups
would also be informative. To that end, I wonder if a Forest plot-like representation of this would
be more suitable?
We thank the reviewer for this suggestion, and have produced a forest plot that allows
readers to clearly see how odds ratios and their 95% confidence intervals vary across IBS
definitions. Whether or not hits from individual definitions replicate is still shown. Where
there is significant heterogeneity between the associations observed under different UK
Biobank-based definitions of IBS, we highlight this. The updated figure, a preview of which is
shown below, replaces the previous Figure S8.
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Figure S8: Concordance between IBS definitions at variant level. Independent
variants significantly associated with IBS in at least one of the IBS definitions along the
y-axis, and their effect on IBS risk (OR and 95% CI, p-value below) across these. While
the direction of effect was generally conserved between IBS definitions, some
associations were only detected under one IBS definition (see e.g. rs116767299 on CHR
2, or r4681686 on CHR 3) and still replicated in an independent dataset (highlighted in
green). Genetic effects at three loci varied significantly between the four UK Biobank
(UKB) definitions of IBS (highlighted in blue, all with pQ≠0<0.05 for Cochran’s Q as a
measure of heterogeneity, Table S14).
Similarly, what was the degree of heterogeneity between the subgroups presented in Table S8 and
the Bellygenes and 23andMe cohorts? The authors note that some associations detected in one
subgroup do “Surprisingly... replicate in an independent dataset”. What were the effect sizes at
these variants in Bellygenes and 23andMe? Is it possible to include these in the Forest plot as
suggested above?
We have included the Bellygenes and 23andMe definitions of IBS in the same forest plot
(Figure S8), as requested.  Additionally, we now show data for the entire pool of UK Biobank
IBS cases and the meta-analysis of Rome-based cases across UK Biobank and the Bellygenes
cohort. Directions of effect for significant hits in any definition remain conserved in these
datasets, as they were across individual definitions of IBS in UK Biobank.
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We would like to thank the reviewer for their suggestions on this figure, as we feel that the
new version is a substantial improvement and makes interpretation of the data across
definitions substantially easier.
I believe the lack of replication of the female-only association with unprompted self-report IBS
from Bonfiglio et al. (2018) warrants further discussion. This seems more odd since the previous
study used largely the same UKB dataset with a noisier definition of IBS. Did the authors also
perform sex-stratified analysis at this variant using their more comprehensive case definition?
Were the results at this variant even nominally significant? Was it significant in their subgroup
analysis using only unprompted self reports?
We agree this is an important point and have spent significant time trying to validate and
understand the female-specific association for IBS reported in Bonfiglio et al. (2018).
Specifically, we have run individual GWAS for each UK Biobank IBS case definition and
subtype (hospital ICD-10, unprompted self-report, DHQ self-report, DHQ Rome III, DHQ
Rome III type C, D and M) with cases and controls restricted to females only, as well as GWAS
attempting to maximize and minimize overlap with the cases used in Bonfiglio et al.
The results of these analyses are now included in Table S15, and are referenced in the Result
section of the main text:
“The female-specific signal previously identified(Bonfiglio et al. 2018) for unprompted
self-reported IBS in UK Biobank was also observed in our female-specific analysis of
unprompted self-reported data, but was not detected in female-specific analyses of any
other case definitions from UK Biobank or the Bellygenes initiative, nor replicated in
23andMe unstratified analyses  of both sexes (Table S15), possibly suggesting survey-specific
factors playing a role.”
While we were able to reproduce the previously reported association using the same case
definition as in the original paper (unprompted self-report in females, p=1.00e-9 for N=6,918
cases, or p=4.29e-10 under 7,130 cases in Bonfiglio et al.), we did not observe the
association in female-specific GWAS where that specific group of cases was excluded
(p=0.63, in a larger group of N=22,309 cases).
Across other UK Biobank case definitions, partially overlapping the self-reported IBS cases,
female-specific p-values ranged between 4.4e-3 and 0.89. Notably, although the SNP was
associated with unprompted self-report of IBS diagnosis at UK Biobank enrollment as
indicated above, it was not associated with prompted self-report of IBS diagnosis as
ascertained in the digestive health questionnaire.
The unprompted self-report and DHQ self-report cases are sourced from responses to
different questions: while the DHQ focuses on gastrointestinal disease and directly asks
about a previous diagnosis of IBS, the IBS cases identified from the unprompted self-report
definition had to have declared they “... had .. serious medical conditions or disabilities”,
which they then identified as IBS in a verbal interview with a qualified nurse. To ascertain
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cases in this way requires the participant to perceive IBS as a ‘serious medical condition’ or
to be more prone to reporting any medical condition as serious. In line with this hypothesis,
the Bonfiglio et al. locus was also reported to associate with the “number of unprompted
self-report illnesses” (p=7.33×10-3 in the Rapid GWAS from the Neale Lab, covering both
sexes).
Please clarify the number of controls in the discovery cohort. On line 173, it says there were
433,201 controls in the discovery cohort (also repeated on line 344). However, summing the
number of controls in UKB (360,845) and Bellygenes (139,981) gives a total of 500,826 controls
(lines 175-176).
There were indeed 433,201 controls in the discovery cohort, and 139,981 controls across the
Bellygenes data. The 360,845 figure is incorrect (that is, in fact, the sum of cohort controls
and UK Biobank controls who did not respond to the DHQ). The correct number of UK
Biobank controls, covering both respondents and non-respondent, is 293,220. We thank the
reviewer for pointing this out, and have corrected it in the text:
“We identified six independent IBS susceptibility loci at genome-wide significance
(p<5×10-8) in a discovery cohort totaling 53,400 cases and 433,201 controls (Fig. 2
and Fig. S5). This results from pooling IBS cases across all case definitions to
maximise power, in a meta-analysis of data from the UK Biobank (40,548 cases,
293,220 controls, Table S1, Table S2) and the international collaborative Bellygenes
initiative (12,852 cases, 139,981 controls, see Methods and Table S9).”
Table S20 - please include an effect size column, or some other indication about direction of effect
of the related phenotype relative to IBS (e.g. does the IBS risk-increasing allele of rs10156602
increase or decrease childhood BMI?).
We thank the reviewer for this suggestion, which is undoubtedly helpful for readers
interested in these specific loci. We have added columns showing the effect and reference
alleles for the association with IBS and the other trait in GWAS catalog (where reported), the
effect allele frequency, and the reported effect (which, in GWAS catalog, varies between
Z-scores and unit decrease/increase). We have also added a column that explicitly states
whether directions of effects are opposite or identical between IBS and the GWAS catalog
trait. This is now Table S22. We added a brief description to the Comparison to previous
GWAS section of the Supplementary Methods:
“Alleles were flipped in order to report GWAS catalogue effect sizes and directions
relative to the IBS risk allele, with allele frequency used to check the consistency of
the alleles (Table S22).“
Given the strong genetic correlations with a range of neuro-related phenotypes, why did the
authors only perform MR analysis on anxiety? Were MR results similar for IBS and the other
phenotypes in Figure 3 with significant rg?
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We have now included Steiger MR analyses on depression, neuroticism, schizophrenia and
bipolar disorder in Table S19 (well-powered non-UK Biobank derived publicly available
summary statistics for insomnia are not available to our knowledge). The finding of
bidirectional causality between IBS<->depression and IBS<->neuroticism are comparable to
IBS<->anxiety (which we picked out as an exemplar), whereas schizophrenia and bipolar
disorder do not show this pattern.
We have added a (very brief) mention of this to the main text:
“Multiple models could explain our data (Table S19), but they were best explained by
shared genetic risk pathways rather than causal effects between the two traits.
Similar complex causal relationships are evident between IBS and other
neuroaffective traits (Table S19).”
The methodology for these analyses is detailed in a new “Mendelian randomization
analyses” section in the Supplementary Text.
“We used unidirectional Mendelian randomization (inverse-variance weighted, IVW)
and bidirectional Mendelian randomization (MR-Steiger),27 implemented in the R
package TwoSampleMR28 (https://github.com/MRCIEU/TwoSampleMR) to test for
evidence of causal effects of anxiety on IBS , using data from an orthogonal study of
anxiety (measured via the GAD-2) in the Million Veterans Program.29 We also carried
out both MR analyses on all significant phenotypes from Figure 3 with non-UK
Biobank summary statistics publicly available. The PubMed IDs of the publication
that the non-IBS summary statistics were taken from are shown in Table S19 (only
non-UK Biobank summary statistics were used to avoid sample overlap).  When IBS
was the exposure, the six discovery loci were used, and when IBS was the outcome,
all independent genome-wide significant associations reported in the corresponding
paper were used.”
In practice, there is a significant amount of additional follow-up that could be carried out
integrating IBS GWAS results with mental health, behavioural and other neuro-related
phenotypes. Ultimately, while our results demonstrate clear shared genetic risk pathways
between mental health and digestive health, they do not pinpoint the precise components of
neuroaffective phenotypes that most strongly associate with IBS. Interpreting these
second-order effects (comparing differences in the genetic relationship between different
traits) would require considerable work on a trait-by-trait basis. We believe that this larger
project is beyond the scope of this paper.
Minor comments
In Table S13, some SE numbers are 0.00E+00
We thank the reviewer for pointing out this formatting error and have corrected this in a new
version of Table S13.
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Line 270-271. I understand what the authors are trying to convey, but I disagree with the
statement that low SNP-heritability is reflected in the low ORs from this study. It is entirely
possible in theory to have low SNP-heritability and large ORs if variants are rare.
We agree that there is not necessarily a 1:1 mapping between effect sizes at common
variants and SNP heritability. The use of the term “reflected” in the text was intended to
indicate that these two findings were consistent with each other, rather than that one
caused the other. To add clarity we have now changed the sentence to state these two
findings separately:
“IBS genome-wide SNP heritability was just 5.8% (SE<0.01) in the European ancestry
population studied here, and the effect sizes of our susceptibility loci were modest
(OR’s <1.05).”
In the description of the GCTA COJO analysis in the supplemental text page 25, please provide the
definition of “upstream”/“downstream”, and specify what individual-level genotype data were
used as the LD reference.
The upstream and downstream boundaries were defined by the clumping, i.e. the leftmost
and rightmost SNPs that had p < 0.05 and at least r2>0.05 with a lead SNP. The reference LD
panel included 10,000 unrelated individuals passing genetic QC. We have updated the
supplementary text to clarify and reflect this:
“We extracted sets of all SNPs between the variants marking the boundaries of each
clump, and used gcta-select in GCTA16 1.92.0 beta 1 to select independently
associated SNPs, and to uncover potential signals attenuated via high-LD SNPs with
opposite effect sizes. We used 10,000 unrelated individuals passing genetic QC in UK
Biobank as a reference LD panel.”
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Reviewer #2:
Remarks to the Author:
This paper reports the results of a large GWAS study of Irritable Bowel Syndrome (IBS) in the UK
Biobank. The authors added a questionnaire to the UK Biobank to collect diagnostic information
on the symptoms, subtypes and severity of IBS. GWAS of a broad phenotypic definition of IBS in
the UK Biobank combined with another large hospital registry consortium, Bellygenes yielded 6
significant associations with SNPS that explained a small proportion of the variance of IBS (i.e.,
5.6%). These findings were replicated in the large 23 and me sample using self-reported diagnosis
of IBS. The other major focus of the paper was investigation of genetic overlap between IBS and
anxiety, neuroticism and depression, which in the aggregate were found to share some genetic risk
with IBS.
This is an interesting paper that seeks to identify the genomics of gut diseases unexplained by well
characterized genetic diseases such as Crohn’s and Ulcerative Colitis. As such, it is an idiopathic and
likely heterogeneous group of conditions that have shared environmental and genetic factors with
a range of other conditions as demonstrated in this report. The finding and replication of 6 loci
advances the field and is of heuristic value for future studies of etiologic mechanisms underlying
subsets of IBS.
However, I found that the second component of the paper that linked IBS to “neuroaffective”
conditions was less compelling. The phenotypes ranged from current symptom checklists for
anxiety and depression that yield highly nonspecific rates of significant mood and anxiety disorders
across varying time periods. Some of the questions are queried over the past 3 months, whereas
others ask about the current two weeks. These scales can all be elevated due to multiple physical
and psychological stressors and have very little relevance to true mental disorders including mood
and anxiety disorders. To date, GWAS have not explained a substantial proportion of these
conditions likely due to the heterogeneity of disorders that may lead to elevated symptoms of
distress. Thus, taken together with the very low explanatory findings for IBS, the link with an even
more heterogeneous group of conditions that may affect the brain does not really advance our
understanding of etiologic factors underlying IBS.
We thank the reviewer for their comments and observations. We agree with the reviewer
that mental health (and the reasons why people fill out a GAD-7 form in a particular way on a
particular day) is complex and multifactorial, and interpreting phenotypic or genetic
correlations with specific measures of mental health is challenging. We do believe that for
researchers studying IBS, the finding of a strong genetic link between IBS and anxiety, and
the demonstration that this is driven, at least in part, by shared genetic pathways rather than
mere co-occurrence, represents a step forward in our understanding of the etiologic factors
of IBS.
In response to this comment we have carried out further analyses to confirm that the genetic
correlation with anxiety and depression that we observe is robust to the way these
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conditions are defined, and does not merely reflect transient increases in scores from
symptom checklists.
First, we have run GWASes of anxiety cases ascertained by four different means:
1. individuals who self-report being diagnosed with anxiety or panic attacks by a doctor,
2. individuals who self-report ever having sought treatment for anxiety,
3. individuals who have a diagnosis of an anxiety disorder (either phobic anxiety
disorder or generalized anxiety disorder) coded in an electronic hospital record since
1997 and
4. individuals who on a GAD-7 symptomatic screening test for generalized anxiety
scored highly (≥10) .
We find nearly identical coheritability estimates (rg point estimates 0.49-0.62) between IBS
and all of the above case definitions.
Second, we have looked at the genetic correlation between IBS and various additional
definitions of major depressive disorder used by the Psychiatric Genomics Consortium (PGC).
This includes definitions from the psychiatric GWAS consortium working group (2013), with
cases required to have “diagnoses of DSM-IV lifetime MDD established using structured
diagnostic instruments from direct interviews by trained interviewers, or
clinician-administered DSM-IV checklists”, and more recent depression GWAS data from
Wray et al. (2018) in which cases ascertained using UK Biobank’s questionnaires (or any other
UK Biobank data) had been excluded. Also from these data, we find high and consistent
genetic correlation between IBS and major depressive disorder (rg point estimates 0.50-0.52).
The above analyses demonstrate that the finding of a genetic correlation between IBS and
anxiety or depression is not related to a particular way of ascertaining the presence of these
conditions. We have added a statement on the robustness of the genetic correlations to the
main text and show the corresponding analyses in a new figure:
“Across the genome, the same alleles that predispose to IBS also predispose to
neuroaffective traits. The correlations were consistent regardless of the mode of
diagnosis of anxiety or depression (Fig. S10).34,35”
A preview of Figure S10 is shown below:
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Figure S10: Genetic correlations (rg) between IBS and various definitions of
anxiety or major depressive disorder (MDD) A. IBS was robustly correlated with
anxiety in UK Biobank, independently of whether anxiety cases were defined by a GAD-7
score≥10, by having sought treatment for anxiety, unprompted self-reporting of
anxiety/panic attacks upon UK Biobank enrolment, or hospital records data in the form
of ICD-10 codes. Controls were required not to have anxiety by any of these definitions.
B. Genetic correlations between IBS and MDD were consistent across different
definitions of MDD. Wray et al. (2018) cases "met standard criteria for MDD, were
directly interviewed [...], or had medical record review by an expert diagnostician", and
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were supplemented by data employing “typical” case inclusion criteria from other
consortia (see publication). We observed no significant difference depending on whether
UK Biobank cases are or are not added to the above (PGC: MDD2 2018 Excluding
23andMe, PGC MDD No UKB / No 23andMe). In data from the Major Depressive Disorder
Working Group of the Psychiatric GWAS consortium (2013, PGC: MDD 2013), cases were
required to have “diagnosis of DSM-IV lifetime MDD established using structured
diagnostic instruments from direct interviews by trained interviewers, or
clinician-administered DSM-IV checklists”. All MDD data are available from the
Psychiatric Genomics Consortium (PGC) website under the exact names provided here.
There are several specific issues that require clarification or discussion.
1. It is unclear why the authors chose to combine across all of the subgroups of IBS for the GWAS
analyses rather than examine the subtypes with greatest diagnostic certainty or severity. The
exceedingly high prevalence rate of IBS of 14.5% was surprising and likely indicates a mixture of
truly heritable cases and those that may be time limited symptom elevations.
The rationale for combining across all of the subgroups is described below. However, we have
also now run two additional analyses on subgroups with greater diagnostic certainty (we
have phrased this as ‘higher-specificity’) and greater severity. For the higher-specificity IBS
diagnosis GWAS, cases had to meet two or more of our case definitions in UK Biobank; and
for the severe IBS GWAS, cases required severe symptoms, defined as IBS-SSS>300. Through
the higher-specificity analysis, we found two replicated loci already presented in this
manuscript (rs150079703 and rs4455799, both found in Table S13, the latter as rs5017929,
with which it is in high LD, r2=0.93). Via the severe IBS GWAS, we found a single locus,
rs9947289, which did not replicate in the 23andMe general IBS dataset (which may reflect
the fact that the 23andMe cases are not specifically severe IBS). Both the high-specificity and
the severe IBS risk profiles are genetically correlated with multiple neuroaffective
phenotypes, echoing the result from the overall discovery cohort. We have amended the
main text and Fig. S11 accordingly:
“We also ran higher-specificity (IBS cases meeting at least two of the four UK
Biobank case definitions, 11,201 cases and 293,220 controls) and high severity
(IBS-SSS>300, 4,296 cases and 72,356 controls) analyses in UK Biobank. The former
produced no novel associations. The latter, while being more heritable (liability-scale
h2=0.42, SE=0.05, Cochran’s Q: 51.7, p=6.31×10-13 compared to discovery cohort
IBS),  produced one association (rs9947289, p=2.80×10-8) that did not replicate
(p=0.57 in the 23andMe data, Table S13). Both of these phenotypes recapitulated
the same genetic correlation with neuroaffective traits as found in the discovery
cohort (Fig. S11).”
A preview of Fig. S11 is shown below:
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Figure S11: Genetic correlations and 95% confidence intervals between various
definitions of IBS and other traits. The selection of traits is identical to that in Figure
3, i.e. traits from peer-reviewed publications in LD Hub most genetically correlated with
IBS, supplemented by traits selected for their clinical relevance (yellow). In the
higher-specificity analysis, we have restricted cases to those meeting at least two of the
four UK Biobank case definitions (Methods). The analysis of severe IBS was limited to
DHQ respondents, with cases having an IBS-SSS>300. Across these definitions of IBS, the
pattern of genetic correlation with neuroaffective traits remains consistent.
For our discovery cohort we chose to combine across all of the case definition subgroups for
a number of key reasons:
1. In order to maximise our sample size – reported by DeBoever et al. (2020) as the
most powerful strategy for detecting susceptibility loci associated with common
traits and diseases.
2. Inclusion of cases identified through our DHQ by the gold standard (at the time our
study was designed) Rome III criteria for IBS allowed identification of 16,009 new
cases compared to those with an existing diagnosis in UK Biobank. We believe it was
the substantial increase in sample size and power that underpinned the success of
our study compared to previously published reports of IBS genetics. Of note
epidemiological studies of IBS have indicated a global prevalence of 11% (Lovell and
Ford 2012) – with estimates of UK prevalence ranging from 6 to 21% depending on
definition (Canavan, West, and Card 2014). Hence the prevalence of IBS that we
observed in UK Biobank is in keeping with the published literature.
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3. Use of the broad, combined definition also allowed generalizability between the UK
Biobank, Bellygenes and 23andMe cohorts. Data relating to diagnostic certainty and
symptom severity were not consistently available for the latter two cohorts.
This approach of combining across all diagnostic definitions was validated by our finding of
high genetic correlation between them:
"To maximise sample size, cases from the four UK Biobank groups were pooled
(n=40,548). This approach was supported by demonstrating high genetic correlations
between them using Linkage Disequilibrium Score Regression (LDSC)48 following a
separate genome-wide association study (GWAS) on each (min. pairwise rg=0.70,
SE=0.06, Fig. S11) and by previous literature on the consistency of genetic results
obtained from different diagnostic definitions in UK Biobank.16"
2. It was difficult to understand the samples and phenotypes for the IBS as well as psychological
symptoms in the 3 samples, and how subsets were combined in the analyses. The Methods could
include a more clear description so that the reader does not have to search the supplementary
materials for this broad overview.
We thank the reviewer for highlighting this lack of clarity and have adjusted the text in the
methods section accordingly to provide an introductory ‘broad overview:
“Our discovery cohort combined cases of IBS identified in the UK Biobank with cases
from the Bellygenes initiative. Replication was sought in an independent panel from
23andMe. Cases ascertained in UK Biobank met at least one of the following four
conditions (the DHQ, or digestive health questionnaire, is viewable online - UK
Biobank resource 595):”
To provide additional information on the ascertainment of IBS subtypes and anxiety and
depression cases, we have added the following text to the methods section:
“Analyses of IBS subtypes were conducted solely using UK Biobank DHQ data based
on standard definitions of IBS-C, IBS-D, IBS-M and IBS-U according to the frequency
of hard or lumpy stools vs loose, mushy or watery stools. Functional constipation and
functional diarrhoea cases were identified similarly, and with the same exclusions
per IBS cases, but (in contrast to the Rome III definition of IBS) needed to have
responded "Never" when asked about the frequency of abdominal pain in the last 3
months. Likewise, analyses of IBS severity (using the IBS-SSS) and associated somatic
symptoms (using PHQ-12) were restricted to DHQ respondents. Anxiety and
depression were identified among UK Biobank participants based on previously
surveyed responses to GAD-7 anxiety and PHQ-9 depression questionnaires,
self-report of diagnosis with depression or anxiety/panic attack, diagnostic codes for
major depression and phobic or generalized anxiety disorder in electronic healthcare
records, or reporting of treatment being sought or offered for these conditions in our
DHQ. See Supplementary Text for details.”
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3. The diagnoses of IBS were quite different in the three samples, ranging from medical records in
the Bellygenes cohort to self-reported questionnaires with dome of the Rome criteria I the UK
Biobank to a few questions in 23 and me. How confident are the authors that they are really
tapping the same disorder using these diverse methods?
IBS is a heterogeneous disorder and given the subjective nature of the symptom-based
diagnostic criteria the extent to which any two people with IBS have the “same disorder” is
debatable. Our strategy for identifying cases was to take a deliberately broad and inclusive
approach that relied on real-world diagnostic criteria for IBS while also maximizing sample
size (key to the success of a genetic study of this type) and generalizability, rather than, e.g.,
restricting ourselves to individuals with the same symptomatically more homogenous
subtype. As a result we do expect to see (and do see) some average differences in
presentation or risk factors across the different case definitions.
However, we do have good evidence that, both phenotypically and genetically, these
different case definitions show substantial overlap, and more importantly that the results
that we present are robust to the specific method of defining IBS.
By examining cases in the UK Biobank who have taken the digestive health questionnaire and
have matched medical records (Figure 1A), we can see that most individuals who had a
medical record for IBS on file also answer “Yes” to the question “Have you been diagnosed
with IBS?” (79%), and are often detected based on Rome III symptom scores at the time of
survey (61%). However, there are also patient subsets within this dataset that are tagged by
the different case definition methods: for instance, the largest single group (48%) is
individuals who have IBS symptoms on the survey but no previous IBS diagnosis. We know
that this group differs in its profile of IBS severity and comorbidities on average from the
other cases, though they are more similar to diagnosed IBS than they are to digestively
healthy controls (Figure 1B, Table S4). Overall, we believe that these methods pick up a
strongly but not perfectly overlapping set of cases with comparable but not identical disease
manifestation.
Regardless of the degree of actual overlap in samples, it is clear that these different case
definitions produce sets of samples that show a substantial genetic overlap. The genetic
correlation, or coheritability, between these different case definitions within UK Biobank
ranges from 70-100% (Figure S13), and the genetic correlation between UK Biobank and
Bellygenes was also very high (99.8%).
Our findings were also consistent across these different case definitions. The six replicating
loci identified in the whole discovery dataset showed consistent evidence of association
across case definitions (shown in a new Figure S8), and the genetic correlation with
neuroaffective traits was significant and highly consistent across all case definitions (Table
S16).
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In conclusion, we are confident that these case definitions encompass phenotypically and
genetically comparable, if not identical, sets of IBS patients. With the approach taken we are
confident that the results we present are not specific to a particular case definition and
generalize across different methods of defining IBS.
4. The epidemiologic associations with IBS in the UK Biobank were quite interesting and could
provide further insight into potential sources of heterogeneity. Could the subtypes of IBS be
further characterized by potential environmental correlates that were described in this report?
We likewise found the epidemiological associations to be interesting. None of these
evidently showed higher correlation with any of the established IBS subtypes (IBS-D, IBS-C or
IBS-M).
Regarding whether the epidemiological characteristics of the patients could be used to
define novel, distinct (and possibly genetically differentiated) subtypes of IBS, we agree that
this would be a potentially valuable use of the UK Biobank digestive health questionnaire
data, but we feel that it is beyond the scope of the current paper. There are multiple other
UK Biobank datasets that could also be used in such an analysis (such as the food frequency
questionnaire and serological screens for pathogens), and we hope that by making the DHQ
available to the community such larger integrative analyses of the genetic, epidemiological
and environmental basis of digestive health will be made possible in the future.
5. The authors should discuss how the 50% response rate to the IBS questionnaire in the UK
Biobank may have led to bias in the findings.
We agree that response bias, both in terms of response rate to the DHQ and in terms of
recruitment biases to UK Biobank itself, could result in the generation of biased or
non-representative findings. Had we not controlled for response bias in our analyses, we
would have seen false positives due to genetic or environmental predictors of survey
response (rather than IBS) - essentially confusing the effects of survey response and of IBS
itself.
We use data for both responders and non-responders in our analyses (where we have data
on both), and correct for differences using a stratified meta-analysis approach. We believe
that this will minimise the effects of bias, and in general we do not see strong heterogeneity
of effect in the association between IBS and genetics for those that did and did not fill out
the survey (for analyses where we have data on both).
While this approach controls for bias, there is also the broader question of how the drop-out
at each stage (recruitment to UK Biobank, followed by responding to the DHQ) will create a
non-representative sample set (previously described in the “Population characteristics” field
of the Nature Research Reporting Summary form). As we allude to in the text, further studies
will be required to test how well these results generalize beyond our dataset to other
(younger, more ethnically diverse) datasets.
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To address this issue we have added the following section (“Controlling for response bias”) to
the supplementary material discussing response bias and how we controlled for it:
“There are systematic differences between respondents and non-respondents.
Respondents have lower rates of IBS as measured via hospital ICD-10 codes (1.16%
vs 1.40% among 171,061 respondents and 317,234 non-respondents, respectively),
but not unprompted self-reporting (2.85% vs 2.30%). They also have lower rates of
neuroaffective conditions based on hospital ICD-10 codes (schizophrenia: 0.04% vs
0.21%, depression: 1.77% vs 3.40%) and unprompted self-reporting (schizophrenia:
0.05% vs 0.16%, depression: 5.83% vs 6.20%). Respondents also had a lower mean
age than non-respondents (64.8 vs 65.8 years when the DHQ data were collected),
and were more often female (56.7% vs 52.9%). Response rates also varied by
ethnicity, e.g. 15.8% (1205 of 7645) among participants who report a Black or Black
British background compared to 36.0% (165243 of 459256) among participants
reporting a White ethnic background. We show that responder effects can also cause
artifactual differences in genetic signals across analyses if not controlled for (Fig.
S14). In our genetic association tests, we therefore analyzed DHQ respondents and
non-respondents separately, and then meta-analyze the results to eliminate the
confounding effect of DHQ response on IBS risk. In non-genetic analysis, e.g.
between IBS and clinical risk factors, we control for DHQ response status by adding it
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Thanks  to  the  authors  for  their  thoughtful  responses  and  changes  to  the  manuscript.  I  agree  it  is  a  
shame  more  could  not  be  done  in  terms  of  obtaining  23andMe  summary  data.  I  have  no  further  
comments.  
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accessible  by  replacing  the  word  “neuroaffective”.  We  spent  a  long  time  during  the  initial  
paper  writing  trying  to  find  the  right  word  to  describe  exactly  what  we  meant,  and  settled  on  
“neuroaffective”,  but  it  is  clear  in  retrospect  that  this  caused  more  confusion  than  
understanding.  The  terms  “mood  and  anxiety”,  while  they  do  not  capture  everything  we  are  
trying  to  describe  explicitly,  do  capture  most  of  it,  and  are  clearly  more  recognizable.   
  
We  prefer  the  use  of  “disorders”  over  “symptoms”,  given  that  the  traits  IBS  was  compared  to  
were  clinical  syndromes  rather  than  individual  symptoms  (as  per  the  most  recent  version  of  
Supplementary  Fig.  10,  which  contains  various  definitions  of  major  depressive  disorder  and  
anxiety  disorders).   
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